Oryon Cell Therapies Raises $21 Million in Series A Funding
Oryon Cell Therapies, a company based in Belmont, Massachusetts, has announced a successful Series A funding round, securing $21 million. This funding will aid the company in advancing its innovative cell therapy solutions aimed at treating neurodegenerative diseases. The round saw participation from investors Neuro.VC and Byers Capital.
Company Background
Oryon Cell Therapies is co-founded by Nikola Kojic, MD-PhD, and Ole Isacson, with Ron Cohen, M.D. serving as the CEO. The company focuses on developing advanced cell therapy techniques to address unmet needs in neurodegenerative disease treatment.
Investors
While the funding round did not have a single lead investor, it was supported by notable venture capital firms Neuro.VC and Byers Capital. These investors are known for their strategic investments in the biotechnology and healthcare sectors, providing both financial support and industry expertise.
Planned Use of Funds
The newly acquired funds will primarily be used to accelerate the development of Oryon Cell Therapies' pipeline of cell therapy products. This includes scaling up research and development efforts, expanding their team with specialized talent, and potentially exploring new markets. The investment will also support the company's efforts in navigating regulatory pathways to bring its therapies to patients more swiftly.
Executive Insights
Ron Cohen, M.D., CEO of Oryon Cell Therapies, emphasized the importance of this funding round in the company's journey. He stated, "This investment allows us to push forward with our mission to develop transformative therapies for patients suffering from neurodegenerative diseases."
Looking Ahead
With this financial backing, Oryon Cell Therapies is well-positioned to make significant strides in the field of cell therapy. The company aims to advance its current projects and explore new therapeutic areas, contributing to the broader goal of improving patient outcomes in neurodegenerative conditions.